X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
female (12) 12
humans (12) 12
index medicus (11) 11
male (11) 11
adult (9) 9
middle aged (9) 9
immunology (8) 8
survival (7) 7
transplantation (7) 7
aged (6) 6
life sciences (6) 6
oncology (6) 6
hla antibodies (5) 5
antibody-mediated rejection (4) 4
graft rejection - immunology (4) 4
metastasis (4) 4
outcomes (4) 4
alloantibodies (3) 3
allografts (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
cancer (3) 3
child (3) 3
complement (3) 3
graft survival (3) 3
histocompatibility antigen hla (3) 3
hla antigens - immunology (3) 3
liver transplantation (3) 3
multivariate analysis (3) 3
oxaliplatin (3) 3
patients (3) 3
predictive value of tests (3) 3
prognosis (3) 3
retrospective studies (3) 3
survival analysis (3) 3
treatment outcome (3) 3
young adult (3) 3
adolescent (2) 2
aged, 80 and over (2) 2
alloantibody (2) 2
allograft-rejection (2) 2
analysis (2) 2
anti-hla antibodies (2) 2
antibodies (2) 2
b cells (2) 2
bacteriology (2) 2
biomarker (2) 2
biopsy (2) 2
cancer therapies (2) 2
care and treatment (2) 2
cetuximab (2) 2
chemotherapy (2) 2
child, preschool (2) 2
cohort studies (2) 2
colorectal cancer (2) 2
colorectal-cancer (2) 2
cross-sectional studies (2) 2
donor-specific antibodies (2) 2
endothelium (2) 2
failure (2) 2
fibrosis (2) 2
follow-up studies (2) 2
gastroenterology & hepatology (2) 2
graft rejection (2) 2
graft rejection - blood (2) 2
graft rejection - diagnosis (2) 2
graft rejection - pathology (2) 2
hematology, oncology and palliative medicine (2) 2
histocompatibility antigens (2) 2
hla histocompatibility antigens (2) 2
immunity, humoral (2) 2
impact (2) 2
infant (2) 2
infiltration (2) 2
isoantibodies - blood (2) 2
isoantibodies - metabolism (2) 2
kidney - immunology (2) 2
kidney - pathology (2) 2
liver (2) 2
liver neoplasms - drug therapy (2) 2
liver neoplasms - secondary (2) 2
logistic models (2) 2
mediated rejection (2) 2
microbiology and parasitology (2) 2
monoclonal antibodies (2) 2
mutation (2) 2
organoplatinum compounds - administration & dosage (2) 2
prevalence (2) 2
quality of life (2) 2
recipients (2) 2
research article (2) 2
revascularization (2) 2
social work (2) 2
subclass (2) 2
surgery (2) 2
syngeneic grafts (2) 2
time factors (2) 2
transplantation of organs, tissues, etc (2) 2
transplants & implants (2) 2
trial (2) 2
tumors (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 8, pp. 819 - 828
Summary Background Gemcitabine plus a platinum-based agent (eg, cisplatin or oxaliplatin) is the standard of care for advanced biliary cancers. We investigated... 
Hematology, Oncology and Palliative Medicine | GROWTH-FACTOR RECEPTOR | MULTICENTER | CISPLATIN | ONCOLOGY | COLORECTAL-CANCER | CLINICAL-TRIALS | GALLBLADDER | COMBINATION | TUMORS | CHEMOTHERAPY | GALL-BLADDER CANCER | ras Proteins - genetics | Peripheral Nervous System Diseases - chemically induced | Proto-Oncogene Proteins p21(ras) | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Alanine Transaminase - blood | Organoplatinum Compounds - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Oxaliplatin | Common Bile Duct Neoplasms - drug therapy | Adult | Bile Ducts, Intrahepatic | Female | Bile Duct Neoplasms - genetics | Cetuximab | Neutropenia - chemically induced | Common Bile Duct Neoplasms - genetics | Bile Duct Neoplasms - drug therapy | Carcinoma - drug therapy | Antibodies, Monoclonal, Humanized - adverse effects | Deoxycytidine - administration & dosage | Gallbladder Neoplasms - genetics | Proto-Oncogene Proteins - genetics | Disease-Free Survival | Gallbladder Neoplasms - drug therapy | Aspartate Aminotransferases - blood | Cholangiocarcinoma - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Intention to Treat Analysis | Cholangiocarcinoma - genetics | Carcinoma - genetics | Aged | Mutation | Deoxycytidine - analogs & derivatives | Chemotherapy | Product development | Gemcitabine | Comparative analysis | Cancer | Index Medicus
Journal Article
Journal of the American Society of Nephrology, ISSN 1046-6673, 02/2015, Volume 26, Issue 2, pp. 457 - 467
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 01/2018, Volume 128, Issue 1, pp. 219 - 232
Journal Article
Liver Transplantation, ISSN 1527-6465, 08/2018, Volume 24, Issue 8, pp. 1091 - 1100
Journal Article
by Emile, Jean-François and Julié, Catherine and Le Malicot, Karine and Lepage, Come and Tabernero, Josep and Mini, Enrico and Folprecht, Gunnar and Van Laethem, Jean-Luc and Dimet, Stéphanie and Boulagnon-Rombi, Camille and Allard, Marc-Antoine and Penault-Llorca, Frédérique and Bennouna, Jaafar and Laurent-Puig, Pierre and Taieb, Julien and Thaler, Josef and Greil, Richard and Gaenzer, Johannes and Eisterer, Wolfgang and Tschmelitsch, Joerg and Keil, Felix and Samonigg, Hellmut and Zabernigg, August and Schmid, Franz and Steger, Günther and Steinacher, Robert and Andel, Johannes and Jagdt, Björn and Lang, Alois and Fridrik, Michael and Függer, Reinhold and Hofbauer, Friedrich and Woell, Ewald and Geissler, Michael and Geissler, Dietmar and Lenauer, Alfred and Prager, Manfred and D'Haens, Geert and Demolin, Gauthier and Kerger, Joseph and Deboever, Guido and Ghillebert, Gilbert and Polus, Marc and Van Cutsem, Eric and Kalantari, Hassan Rezaie and Delaunoit, Thierry and Goeminne, Jean Charles and Peeters, Marc and Vergauwe, Philippe and Houbiers, Ghislain and Humblet, Yves and Janssens, Jos and Schrijvers, Dirk and Vanderstraeten, Erik and Vermorken, Jan and Van Daele, Daniel and Ferrante, Michel and Forget, Frederic and Hendlisz, Alain and Yilmaz, Mette and Nielsen, Svend Erik and Vestermark, Lene and Larsen, Jim and Zawadi, Mohamed-Ayman and Bouche, Olivier and Mineur, Laurent and Bennouna-Louridi, Jaafar and Dourthe, Louis Marie and Ychou, Marc and Boucher, Eveline and Pezet, Denis and Desseigne, Francoise and Ducreux, Michel and Texereau, Patrick and Miglianico, Laurent and Rougier, Philippe and Fratte, Serge and Levache, Charles-Briac and Merrouche, Yacine and Ellis, Stephen and Locher, Christophe and Ramee, Jean-Francois and Garnier, Claire and Viret, Frederic and Chauffert, Bruno and Cojean-Zelek, Isabelle and Michel, Pierre and Lecaille, Cedric and Borel, Christian and Seitz, Jean-Francois and Smith, Denis and Lombard-Bohas, Catherine and Andre, Thierry and Gornet, Jean-Marc and Fein, Francine and Coulon-Sfairi, Marie-Aude and Kaminsky, Marie-Christine and Lagasse, Jean-Paul and Luet, Dominique and Etienne, Pierre-Luc and ... and PETACC8 Study Investigators and Istituto Oncologico Romagnolo (IOR) and Fédération Nationale des Centres de Lutte Contre le Cancer Association Européenne de Recherche en Oncologie (AERO) and Gruppo Cooperativo do Cancro Digestivo da Associação Portuguesa de Investigação Oncológica (GCCD, APIO) and Lone Nørgård Petersen and Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD) and Austrian Breast and Colorectal cancer Study Group (ABCSG) and Belgian Group of Digestive Oncology (BGDO) and Gruppo Cooperativo Chirurgico Italiano (GOCCI) and John Allen Bridgewater and Gruppo Oncologico dell'Italia Meridionale (GOIM) and Fédération Francophone de Cancérologie Digestive (FFCD) and Gruppo Oncologico Nord Ovest (GONO) and Fédération Nationale des Centres de Lutte Contre le Cancer (UNICANCER) and Grupo Español para el Tratamiento de los Tumores Digestivos (TTD) and Arbeitsgemeinschaft Internistische Onkologie (AIO) and Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)
European Journal of Cancer, ISSN 0959-8049, 09/2017, Volume 82, pp. 16 - 24
Journal Article
FRONTIERS IN IMMUNOLOGY, ISSN 1664-3224, 03/2019, Volume 10, pp. 513 - 513
Clinical outcome in antibody-mediated rejection (AMR) shows high inter-individual heterogeneity. Sialylation status of the Fc fragment of IgGs is variable,... 
SURVIVAL | COMPLEMENT | BIOMARKER | ANTI-HLA ANTIBODIES | glycosylation | IMMUNOLOGY | FAILURE | antibody-mediated rejection | sialylation | DSA | solid organ transplantation | IGG-FC | IMMUNOGLOBULIN-G | Life Sciences | Human health and pathology
Journal Article
American Journal of Hematology, ISSN 0361-8609, 08/2018, Volume 93, Issue 8, pp. 994 - 1001
Matching for HLA‐A, ‐B, ‐C, and ‐DRB1 loci (8/8 match) is currently the gold standard for unrelated donor hematopoietic cell transplantation (HCT). In Europe,... 
SURVIVAL | IMPACT | OUTCOMES | HEMATOLOGY | HLA-DPB1 DISPARITY | Stem cell research | Histocompatibility antigens | Mortality | HLA histocompatibility antigens | Stem cells | Transplantation | Hematopoietic stem cells | Graft-versus-host reaction | Typing | Transplants & implants | Drb1 protein | Malignancy | Histocompatibility antigen HLA | Tissue typing | Morbidity | Quality of life | Hemopoiesis | Life Sciences
Journal Article
Douleurs, ISSN 1624-5687, 12/2018, Volume 19, Issue 6, pp. 255 - 257
Journal Article
Transplantation, ISSN 0041-1337, 07/2018, Volume 102 Suppl 7S-1, pp. S48 - S48
BACKGROUNDNatural Killer cells (NK) are effectors of the innate immune system carrying inhibitory KIR, which regulate the killing function of these cells by... 
SURGERY | IMMUNOLOGY | TRANSPLANTATION
Journal Article
Nephrology Dialysis Transplantation, ISSN 0931-0509, 05/2015, Volume 30, Issue suppl_3, pp. iii37 - iii37
Journal Article
Journal Article
Journal Article